2 blue chip healthcare shares you should own

Every investor should consider these 2 healthcare giants.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

a woman

The economy is made up of a number of different sectors and businesses. The healthcare industry is one of the best sectors to invest your money in my opinion.

Here are a few reasons why you should consider Cochlear Limited (ASX: COH) and CSL Limited (ASX: CSL).

Defensive earnings

Healthcare offers shareholders a defensive earnings profile because of how integral the product or service is.

People will value being alive and healthy over most other things in life.

CSL offers a variety of services like plasma products, vaccines and pharmaceuticals which users will all value over a trip to the movies and other lifestyle expenses.

Cochlear gives its users a life changing ability to improve their hearing with hearing implants.

Ageing demographics

There is a unique set of circumstances happening now and over the next few decades where the population of people older than 65 is going to significantly increase. This should be a big boost to all the companies that benefit from elderly customers. Cochlear and CSL could be two of the biggest winners.

International expansion

Australia has a small population and it doesn't offer much room for growth. If a business can successfully expand overseas then the world becomes their oyster.

CSL and Cochlear both earn a large majority of their earnings from overseas and I imagine this will continue to be the case as they grow in Europe and North America.

Time to buy?

Cochlear is trading at 38x FY18's estimated earnings and CSL is trading at 30x FY18's estimated earnings.

Both shares are wonderful businesses but I don't think they're buys at the current prices. I'd wait until they're both at least 15% to 20% cheaper before buying over the next six months.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A stressed businessman sits next to his briefcase with his head in his hands, while the ASX boards behind him show shares crashing.
52-Week Lows

CSL's collapse deepens. Why this ASX giant can't find a floor

CSL shares hit a 9-year low as new demand concerns emerge.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Prediction: CSL shares could surpass $265 in 2026

CSL shares are tumbling again on Wednesday. Here's what it'll take for the price to take a u-turn.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

Why are Cochlear shares down 36% today?

The medical device manufacturer has delivered a bitter pill for shareholders.

Read more »

Health professional working on his laptop.
Healthcare Shares

Are ASX healthcare shares the next to rally?

This sector has plenty of opportunity long term.

Read more »

a woman puts her fingers in her ears with a pained expression on her face with her eyes closed as though trying to block hearing bad news or an unpleasant loud noise.
Healthcare Shares

Cochlear cuts FY26 earnings outlook amid softer sales

Cochlear reduces its FY26 earnings guidance amid softer implant sales, ongoing challenges in key markets, and a focus on long-term…

Read more »

A man sits nervously at his computer with his mouth resting against his hands clasped in front of him as he stares at the screen of his computer on a home desk.
Healthcare Shares

EBOS Group trims FY26 earnings guidance as fuel costs bite

EBOS Group trims FY26 earnings guidance as elevated fuel costs weigh on its healthcare distribution businesses.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

This ASX biotech stock could more than double Canaccord Genuity says

This company has more than one iron in the fire.

Read more »

A medical researcher wearing a white coat sits at her desk in a laboratory conducting a test.
Healthcare Shares

This ASX biotech's shares just hit a new 12-month high, up more than 700% over a year. Here's why

Good news has this company's shares on the up.

Read more »